Basilea Pharmaceutica Ltd BPMUF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $50.00
- Day Range
- $41.00–41.00
- 52-Week Range
- $41.00–52.00
- Bid/Ask
- $41.10 / $57.12
- Market Cap
- $490.21 Mil
- Volume/Avg
- 7 / 7
Key Statistics
- Price/Earnings (Normalized)
- 8.61
- Price/Sales
- 2.86
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 143
- Website
- https://www.basilea.com
Valuation
|
Metric
|
BPMUF
|
|---|---|
Price/Earnings (Normalized) | 8.61 |
Price/Book Value | 29.47 |
Price/Sales | 2.86 |
Price/Cash Flow | 7.95 |
Price/Earnings
BPMUF
Financial Strength
|
Metric
|
BPMUF
|
|---|---|
Quick Ratio | 2.26 |
Current Ratio | 2.77 |
Interest Coverage | 5.69 |
Quick Ratio
BPMUF
Profitability
|
Metric
|
BPMUF
|
|---|---|
Return on Assets (Normalized) | 25.59% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 39.87% |
Return on Assets
BPMUF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hscrl | $454.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hdndrl | $90.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Djwvjhc | $89.7 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Vhnbb | $40.2 Bil | |
MRNA
| Moderna Inc | Gnk | $30.5 Bil | |
ARGX
| argenx SE ADR | Jdc | $27.3 Bil | |
BNTX
| BioNTech SE ADR | Jnr | $23.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fzzgnr | $21.7 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dccft | $17.8 Bil | |
INCY
| Incyte Corp | Phrfll | $12.3 Bil |